| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
No pharmacological target. The compound is a deuterated phospholipid standard, not a receptor ligand or enzyme inhibitor. Its analytical role is to co-elute with the unlabeled 14:0 PE analyte and provide a distinct mass transition in LC-MS/MS, correcting for matrix effects, extraction recovery, and ionization variability across lipidomic samples. The fully deuterated acyl chains preserve the physicochemical behavior of the phospholipid while shifting its mass by +54 Da.
|
|---|---|
| ln Vitro |
In the process of developing new drugs, stable heavy isotopes of carbon, hydrogen, and other elements have been added to pharmacological molecules, mostly as quantitative tracers. Due to its potential effects on medication pharmacokinetics and metabolic properties, deuteration is a matter for worry [2].
No intrinsic biological activity (IC50, EC50, or receptor affinity) is applicable, because the compound is an analytical reference material. Relevant specifications include isotopic enrichment, chemical purity, and the integrity of the deuterated acyl chains. Deuterated fatty acids can undergo hydrogen–deuterium exchange at the alpha carbon to the carbonyl, so the isotopic distribution should be monitored to ensure that the +54 Da transition remains the dominant species for accurate quantification. |
| ln Vivo |
No in vivo therapeutic efficacy is expected. In vivo, the compound is used as an internal standard in lipidomic analyses of PE species in tissues and biofluids, enabling accurate comparison of phosphatidylethanolamine levels across biological samples and supporting isotope-dilution quantification workflows.
|
| Enzyme Assay |
In the analytical workflow, 14:0 PE-d54 is spiked into lipid extracts prior to LC-MS/MS analysis. Phosphatidylethanolamines are typically analyzed in negative ion mode, and the transition corresponding to the unlabeled 14:0 PE and the +54 Da transition of the deuterated standard are monitored. The peak area ratio provides the basis for quantification against calibration standards, correcting for recovery and ion suppression.
|
| Cell Assay |
In cell-based lipidomics, cells are cultured under experimental conditions, lipids are extracted, and the deuterated standard is added before analysis. LC-MS/MS quantification of PE species uses the internal standard to normalize for recovery and ionization, enabling absolute or relative quantification of 14:0 PE and related phospholipids in cell lysates.
|
| Animal Protocol |
In animal studies, tissues or plasma are collected, spiked with 14:0 PE-d54, and subjected to lipid extraction. LC-MS/MS analysis uses the internal standard to correct for recovery and matrix effects, allowing accurate determination of PE concentrations and comparison across treatment groups. No stand-alone efficacy protocol applies because the compound is an analytical reference material.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
|
| Molecular Formula |
C33H66NO8P
|
|---|---|
| Molecular Weight |
635.853
|
| Exact Mass |
689.791
|
| CAS # |
326495-41-4
|
| Related CAS # |
(2R)-3-(((2-Aminoethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl ditetradecanoate;998-07-2
|
| PubChem CID |
46891713
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
685.6±65.0 °C at 760 mmHg
|
| Flash Point |
368.5±34.3 °C
|
| Vapour Pressure |
0.0±4.6 mmHg at 25°C
|
| LogP |
11.58
|
| tPSA |
139
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
35
|
| Heavy Atom Count |
43
|
| Complexity |
686
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([2H])([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H]
|
| InChi Key |
NEZDNQCXEZDCBI-QHDWWDETSA-N
|
| InChi Code |
InChI=1S/C33H66NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-32(35)39-29-31(30-41-43(37,38)40-28-27-34)42-33(36)26-24-22-20-18-16-14-12-10-8-6-4-2/h31H,3-30,34H2,1-2H3,(H,37,38)/t31-/m1/s1/i1D3,2D3,3D2,4D2,5D2,6D2,7D2,8D2,9D2,10D2,11D2,12D2,13D2,14D2,15D2,16D2,17D2,18D2,19D2,20D2,21D2,22D2,23D2,24D2,25D2,26D2
|
| Chemical Name |
2-azaniumylethyl [(2R)-2,3-bis(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptacosadeuteriotetradecanoyloxy)propyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5727 mL | 7.8635 mL | 15.7270 mL | |
| 5 mM | 0.3145 mL | 1.5727 mL | 3.1454 mL | |
| 10 mM | 0.1573 mL | 0.7863 mL | 1.5727 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.